PUBLICATIONS: 

Patents

*IRE1 inhibitor in combination with cancer therapeutic agent for cancer treatment. International Patent Number PCT/CN2018/113783.

*Val(8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome. Patent Number: 8,642,548.

*Glucagon-like-peptide 1 (GLP-1) pharmaceutical formulations. Patent Number: 07760728.1-2108 PCT/US2007066728.

*Metallotetropyrolic photosensitizing agents for use in photodynamic therapy. Patent Number US682792B2 / US20050137180A1.

 

Journal Articles and Book Chapters

*Book Chapter 2.3; Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals; Editors: Cavagnaro JA, Cosenza ME; 2022.

​

 *Long-term nonclinical pulmonary safety assessment of Afrezza, a novel insulin inhalation powder. Toxicologic Pathology, Supplement 1-15, 2020.

​

 *IRE1-XBP1s pathway promotes prostate cancer by activation c-MYC signaling. Nature Communications, December 2018.

​

 ​*Sigma receptors [Rs]: Biology in normal and diseased states. Journal of Receptors and Signal Transduction, May, 2015.

 

*Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analogue ROSE-010 delivered by pulmonary and systemic routes in the conscious rat. Regulatory Peptides, 2012, 179 (1-3): 71-6.

*Evaluation of novel particles as an inhalation system for GLP-1. Diabetes, Obesity and Metabolism, 11, 2009, 1050-1059.

*Serum 2 macroglobulin and 1 inhibitor 3 concentrations are increased in hypoalbuminemia by post translational mechanisms. Kidney International, 1998 Jan, 53(1):67-75.

*Longevity in obese and lean male and female rats of the Zucker strain: Prevention of hyperphagia. American Journal Clinical Nutrition, 1997 66:1-14.

*Administration of arachidonic acid in vivo alters muscle fatty acid composition and insulin secretion in obese rats. International Journal of Obesity, 12:26-32, 1997.

*Insulin secretion in obese-derived islets is normalized with in vivo administration of arachidonic acid. Obesity Res, 29:245-255, 1997.

*The male obese Wistar Diabetic Fatty rat is a new model of extreme insulin resistance. Obesity Res 2: 432-443, 1994.

*Use of glycated hemoglobin to assess strain differences and age changes in Wistar Diabetic Fatty rats and Zucker fatty rats. Obesity Research 2: 535-540, 1994.

*Studies in the Wistar Diabetic Fatty rat (fa/fa): A model of NIDDM. In: Lessons in Animal Diabetes V, 75-82, E. Shafrir (ed.), 1993. 

*Effect of the beta-adrenergic agonist, isoproterenol, on protein deposition and adipose cellularity of chickens. Proceeding of Poultry Science, 1988.

*Effect of dietary or in ovo isoproterenol administration on growth and fattening of broilers. Poultry Science, 1988. 

 

Abstracts 

*Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors. ASCO Oral presentation June, 2023.

​

*A Phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors. ASCO Poster Session June, 2021.

 

* Long-Term Pulmonary Nonclinical Safety Assessment of Afrezza®, a Novel Insulin Inhalation Powder, J Tox Path; 120, July, 2019.

​

*Inhibition of IRE1α RNase activity modulates the secretome of Triple Negative Breast Cancer cells and enhances the effectiveness of chemotherapy. European Cell Death Organization, 2016.

*Preliminary safety assessment of a novel IRE1α–inhibitor in rats. The Toxicologist 2015.

*Preclinical Long Term Safety Assessment of Technosphere Insulin (Afrezza). The Toxicologist; 120 (Suppl 2): 175, 2013.

*Long Term Pulmonary Safety Assessment of Technosphere Insulin (Afrezza) in Rats and Dogs. The Toxicologist; 120 (Suppl 2): 175, 2011.

*Formulation/Device Combination for Systemic Drug Delivery by Inhalation. Inhalation. 2009.

*Mimicking Endogenous Peptide Secretion by Inhalation. AAPS, 2009.

*Immunology poster AACR Tumor Immunology Meeting, Miami, Dec 2009.

*Synergy of Technosphere Insulin Inhalation Powder Used in Combination with Other Diabetes Medications in the Obese Zucker Diabetic Rat. Diabetes, 2008.

*GLP-1 Superior Systemic Pharmacokinetics After Pulmonary Delivery as MKC253 Compared to Intravenous or Subcutaneous Routes in Rats. Diabetes. 2008.

*Oxyntomodulin and Peptide YY Pulmonary Delivery by Technosphere Particles: Decreased Food Intake in Normal and Diabetic Rats. Diabetes Technology, 2008.

*Effects of GLP-1 Technosphere Powder Administered by Pulmonary Insufflations in Male Obese Zucker Diabetic Fat Rats. Diabetes 2007.

*Development of GLP-1 Technosphere Powder: An Inhaled GLP-1 Product. Diabetes, 2007.

*Bone Growth in Juvenile Dogs with Administration of Cinacalcet. American Society of Bone Mineral Research. ASBMR, Oct, 2004.

*Hemolytic potential of vehicles used for rapid in vivo screening of small molecules. Society of Toxicology, 41st Annual Meeting, Nashville Tennessee, 2002.

*A Comparison of the Sensitivity of Detection of the Hepatotoxicity of Allyl Alcohol in the Rat Using 1H NMR of Urine Versus Histopathology and Clinical Pathology.

*Metabonomics: A sensitive technique to assess toxicity. SMDD poster session, May 25, 2002.

*Photodynamic therapy and topical application of the new photosensitizer MV6401. International Photodynamic Association, 8th World Congress of Photodynamic Medicine, 2001.

*MV6401: A new potent photosensitizer for photodynamic therapy. International Photodynamic Association, 8th World Congress of Photodynamic Medicine, 2001.

*Prevention of hyperphagia normalizes median lifespan and delays the onset of renal disease in male and female genetically obese Zucker rats (fa/fa). IV Benjamin Franklin Symposium. La NaPoule, France. 1996.

*Administration of arachidonic acid in vivo alters skeletal muscle phospholipid fatty acid composition and food intake in obese Zucker (fa/fa) and Wistar Diabetic Fatty (fa/fa) rats. Obesity Research, 1996.

*Arachidonic acid administration in vivo alters PGE2 release and decreases insulin secretion in pancreatic islets from obese Zucker rats and obese, diabetic rats. Diabetes, 1995.

*Delayed onset of degenerative renal disease in pair-fed genetically obese female Zucker rats compared to ad-libitum fed genetically obese female rats and pair-fed obese male rats. Gerontological Society of America, 48th Annual Science Meeting, Los Angeles, CA, 1995.

*Modest food restriction influences survival in aging obese male and female Zucker rats. Gerontological Society of America, 48th Annual Science Meeting, Los Angeles, CA, 1995.

*Differences in glucose-stimulated phospholipid metabolism in lean and obese Zucker rats. Obesity Research Supplement 1995.

*Obesity and Longevity: A longitudinal study of obese and lean Zucker rats. American Society Clinical Nutrition 35th Annual Meeting, San Diego, CA, 1995.

*Administration of arachidonic acid in vivo decreases insulin secretion in pancreatic islets isolated from obese (fa/fa) Zucker rats. International Journal of Obesity, 18 (Suppl 3):0447, 1994.

*The role of arachidonic acid in insulin hypersecretion of the obese Zucker rat. American Diabetes Association 29th Research Symposium & ICO Satellite Conference, August, Boston MA, 1994.

*Obesity and hyperinsulinemia: a role for arachidonic acid. American Diabetes Association 29th Research Symposium & ICO Satellite Conference, August, Boston MA, 1994.

*Sexual dimorphism and age changes in glycated hemoglobin of Wistar Diabetic Fatty rats. Diabetes 42 (Suppl 1):48A, 1993.

Morphological investigations of endocrine pancreas from obese Wistar Diabetic Fatty rats: comparison with Zucker rats. Obesity Research 1, (Suppl 2):101S, 1993.

*Glucose homeostasis measured by glycated hemoglobin on obese Wistar Diabetic Fatty (WDF) rats and Zucker obese rats. International Congress Nutrition, Adelaide, Australia, Sept. 1993.

*High sucrose diet alters insulin receptor number and binding affinity and tyrosine kinase activity in the Wistar Diabetic Fatty (WDF) rats. FASEB J, 6:A1647, 1992.

*Muscle insulin receptor tyrosine kinase activity and adipose cellularity is altered in male obese Wistar Diabetic Fatty (WDF) rats. International Journal of Obesity, 16 (Suppl.1):P173, 1992.

*Muscle insulin receptor tyrosine kinase (TK) activity is directly related to plasma glucose and insulin concentration in male Wistar Diabetic Fatty rats. J American Diabetes Association 41:144A, 1992.

*In ovo administration of triiodothyronine enhances broiler responsiveness to a dietary beta-adrenergic agonist. FASEB J, 3:A102, 1989.